Actavis Indonesia operations began on November 8, 1969, with the inauguration by the late President of the Republic of Indonesia at the time, Mr. HM. Soeharto, as PT. Dumex Indonesia which was one of the first multinational company which have full operation in Indonesia. In 1983 PT. Dumex Indonesia was acquired by Alpharma, then the new company’s name was modified to be PT. Dumex – Alpharma Indonesia, and in 2001 it was changed to be PT. Alpharma, focusing in Ethical and OTC business.

Today, PT. Actavis Indonesia is a part of Actavis Generics and is focusing on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. In July 2015, Allergan, Plc announced it would sell the Generics division of the company (Actavis Generics) to Teva Pharmaceuticals for $40.5 billion, the transaction was completed in the beginning of Aug 2016.

Our portfolio is the best-in-class products that provide valuable treatments for the central nervous system, gastroenterology, women’s health, cardiovascular, oncology and anti-infective therapeutic categories, and operates the biggest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines in approximately 80 countries. Our R&D focused on strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios.

• Company: PT. Actavis Indonesia
• Year Established: 1969
• Address: Raya Bogor km. 28 Jakarta 13710, Indonesia
• Phone: +62 21 7592 4640/ +62 21 871 0311
• Fax: +62 21 7592 4641/ +62 21 871 1382
• Email: [email protected] / [email protected] / [email protected]
• Website: actavis.co.id

Products: Generic Medicines, Specialty Medicines